Biomarker Panel Improves Detection of Breast Cancer
- Detailed Technology Description
- A non-invasive test for breast cancer (BC) detection measures DNA methylation using a unique panel of gene biomarkers.
- *Abstract
-
A non-invasive test for breast cancer (BC) detection measures DNA methylation using a unique panel of gene biomarkers. Designed for cancer screening and diagnosis, the test relies on an assay type known to be stable and can be performed on any bodily fluid permitting extraction and concentration of nucleic acids, including blood and urine. This patent-pending technology uses measures of aberrant DNA methylation gene patterns, which have been linked to BC. In a pilot study, the composite biomarker panel demonstrated 100 percent specificity and 97 percent sensitivity for BC detection. Because sample analysis can occur in any clinical lab setting, the test has the potential to be incorporated into national cancer screening programs.
This technology is part of KAUST’s technologycommercialization program that seeks to stimulate development and commercialuse of KAUST-developed technologies. Opportunities exist for joint development,patent licensing, or other mutually beneficial relationships.
- Country/Region
- USA
